The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial
Open accessAbstract
Importance: Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown. Objective: To determine whether treatment with sertraline improves depressive symptoms in patients with CKD and MDD. Design, Setting, and Participants: The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CKD, who were enrolled at 3 US medical centers. The Mini Neuropsychiatric Interview was used to establish MDD. The first participant was randomized in March 2010 and the last clinic visit occurred in November 2016. Interventions: After a 1-week placebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks at an initial dose of 50 mg/d (escalated to a maximum dose of 200 mg/d based on tolerability and response) or matching placebo (n = 99). Main Outcomes and Measures: The primary outcome was improvement in depressive symptom severity from baseline to 12 weeks determined by the 16-item Quick Inventory of Depression Symptomatology-Clinician Rated (QIDS-C16) (score range, 0-27; minimal clinically important difference, 2 points). Secondary outcomes included improvement in quality of life (Kidney Disease Quality of Life Survey-Short Form; score range, 0-100; higher scores indicate more favorable quality of life) and adverse events. Results: There were 201 patients (mean [SD] age, 58.2 [13.2] years; 27% female) randomized. The primary analysis included 193 patients who had at least 1 outcome assessment after randomization. The mean (SD) baseline QIDS-C16 score was 14.0 (2.4) in the sertraline group (n = 97) and 14.1 (2.4) in the placebo group (n = 96). The median participation time was 12.0 weeks and the median achieved dose was 150 mg/d, which was not significantly different between the groups. The QIDS-C16 score changed by -4.1 in the sertraline group and by -4.2 in the placebo group (between-group difference, 0.1 [95% CI, -1.1 to 1.3]; P = .82). There was no significant between-group difference in change in patient-reported overall health on the Kidney Disease Quality of Life Survey (median score, 0 in the sertraline group vs 0 in the placebo group; between-group difference, 0 [95% CI, -10.0 to 0]; P = .61). Nausea or vomiting occurred more frequently in the sertraline vs placebo group (22.7% vs 10.4%, respectively; between-group difference, 12.3% [95% CI, 1.9% to 22.6%], P = .03), as well as diarrhea (13.4% vs 3.1%; between-group difference, 10.3% [95% CI, 2.7% to 17.9%], P = .02). Conclusions and Relevance: Among patients with non-dialysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not significantly improve depressive symptoms. These findings do not support the use of sertraline to treat MDD in patients with non-dialysis-dependent CKD. Trial Registration: clinicaltrials.gov Identifier: NCT00946998.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with major depression and non-dialysis-dependent chronic kidney disease, sertraline did not significantly improve depressive symptoms compared with placebo over 12 weeks144.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B. M., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J. Z., Balkrishnan, R., Bragg‐Gresham, J. L., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,192
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Biological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F. G., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,309 · cited 1×
“A high placebo response has been postulated to be associated with negative trials of antidepressant medications.(35) However, the4-pointdecrease in theQIDS-C16 score in theplacebo group is lower thanwhat is considered a “high” placebo response rateobserved indepression treatment trials.”
Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument
Hays, R. D., Kallich, J. D., Mapes, D., Coons, S. J., & Carter, W. B. (1994) · Quality of Life Research · doi:10.1007/bf00451725 · Cited by 1,235
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 5×
“Few data exist regarding SSRI safety among patients with CKD because such patients have been excluded from large antidepressant medication trials.(12,13,39) Patients with advanced CKD are at a higher risk for antidepressant adverse events due to the potential accumulation of toxic metabolite effects in the setting of…”
InfluentialSelf-citationPalmer, S., Vecchio, M., Craig, J. C., Tonelli, M., Johnson, D. W., Nicolucci, A., Pellegrini, F., Saglimbene, V., Logroscino, G., Fishbane, S., et al. (2013) · Kidney International · doi:10.1038/ki.2013.77 · Cited by 925
Lash, J. P., Go, A. S., Appel, L. J., He, J., Ojo, A., Rahman, M., Townsend, R. R., Xie, D., Cifelli, D., Cohan, J., et al. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00070109 · Cited by 619
Weisbord, S. D., Fried, L. F., Arnold, R. M., Fine, M. J., Levenson, D. J., Peterson, R. A., & Switzer, G. E. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020157 · Cited by 567 · cited 1×
“Depression also significantly worsenedpatient-centeredoutcomesandwasassociatedwith dialysis initiation, lower quality of life, greater symptomburden,sexualdysfunction,andnonadherencetomedicationsand dietary restrictions.(10,11) Evidence for placebo-controlled efficacy of commonly used antidepressants, such as selectiv…”
Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure
O'Connor, C. M., Jiang, W., Kuchibhatla, M., Silva, S. G., Cuffe, M. S., Callwood, D. D., Zakhary, B., Stough, W. G., Arias, R. M., Rivelli, S. K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.068 · Cited by 535
Kimmel, P. L., Peterson, R. A., Weihs, K. L., Simmens, S. J., Alleyne, S. I., Cruz, I., & Veis, J. H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00059.x · Cited by 533
SAFTEE: a technique for the systematic assessment of side effects in clinical trials.
Levine, J., & Schooler, N. (1986) · PubMed · Cited by 330
Hedayati, S. S., Bosworth, H. B., Briley, L. P., Sloane, R. J., Pieper, C. F., Kimmel, P. L., & Szczech, L. A. M. (2008) · Kidney International · doi:10.1038/ki.2008.311 · Cited by 294
Self-citationAngermann, C. E., Gelbrich, G., Störk, S., Gunold, H., Edelmann, F., Wachter, R., Schunkert, H., Graf, T., Kindermann, I., Haass, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.7635 · Cited by 292
Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects
Wisniewski, S. R., Rush, A. J., Balasubramani, G. K., Trivedi, M. H., & Nierenberg, A. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200603000-00002 · Cited by 288 · cited 1×
“3; score range, 0-100; higher scores signify more favorable quality of life),(22) which were administered at baseline and at 6 and 12 weeks; (3) adverse events and tolerability assessed by the occurrence of serious adverse events (ie, death, dialysis initiation, hospitalizations, or bleeding requiring transfusion), ma…”
Self-citationHedayati, S. S. (2010) · JAMA · doi:10.1001/jama.2010.619 · Cited by 266
Self-citationPrevalence of Major Depressive Episode in CKD
Hedayati, S. S., Minhajuddin, A. T., Toto, R. D., Morris, D. W., & Rush, A. J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.017 · Cited by 205 · cited 2×
“20 Prespecified secondary outcomes included (1) response (≥50% decrease in baseline QIDS-C16 score) and remission (score decrease to ≤5); (2) quality-of-life end points and overall functioning assessed by the 5-item Work and Social Adjustment Scale (WSAS; in which each item is rated on a 0-8 Likert scale with 0 indica…”
Self-citationAssociation between depression and death in people with CKD: a meta-analysis of cohort studies
Palmer, S. C., Vecchio, M., Craig, J. C., Tonelli, M., Johnson, D. W., Nicolucci, A., Pellegrini, F., Saglimbene, V., Logroscino, G., Hedayati, S. S., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.369 · Cited by 201
Self-citationBoulware, L. E., Liu, Y., Fink, N. E., Coresh, J., Ford, D. E., Klag, M. J., & Powe, N. R. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00030505 · Cited by 183
Hedayati, S. S., Grambow, S. C., Szczech, L. A., Stechuchak, K. M., Allen, A. S., & Bosworth, H. B. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.07.002 · Cited by 137
Self-citationValidation of Depression Screening Scales in Patients With CKD
Hedayati, S. S., Minhajuddin, A., Toto, R. D., Morris, D. W., & Rush, A. J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.016 · Cited by 136 · cited 11×
“This instrument was previously validated for depression screening and shown to be independently associatedwith outcomes among individuals with CKD.(16,17) Individuals who provided consent completed the Mini International Neuropsychiatric Interview,(18) which is based on the Diagnostic and Statistical Manual of Mental…”
InfluentialSelf-citationFluoxetine in Depressed Patients on Dialysis
Blumenfield, M., Levy, N. B., Spinowitz, B., Charytan, C., Beasley, C. M., Dubey, A. K., Solomon, R., Todd, R., Goodman, A. I., & Bergstrom, R. F. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/wq33-m54t-xn7l-v8mx · Cited by 133
Koo, J.-R., Yoon, J.-Y., Joo, M.-H., Lee, H., Oh, J., Kim, S.-G., Seo, J., Lee, Y., Kim, H.-J., Noh, J., et al. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200501000-00001 · Cited by 108
Brown, E. S., Vigil, L., Khan, D. A., Liggin, J. D. M., Carmody, T. J., & Rush, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.030 · Cited by 99
Self-citationFriedli, K., Guirguis, A., Almond, M. K., Day, C. J., Chilcot, J., Silva‐Gane, M. D., Davenport, A., Fineberg, N. A., Spencer, B. W. J., Wellsted, D. M., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02120216 · Cited by 95 · cited 1×
“Only 2 trials appropriately diagnosedMDD by using a psychiatric interview, one of which includedonly 14patients treatedover8weeks(32)and the other, 30 patients over 6 months.(27) Neither showed an antidepressant treatment effect.”
Rosenthal, D. S., Halen, N. V., & Cukor, D. (2012) · Hemodialysis International · doi:10.1111/j.1542-4758.2012.00688.x · Cited by 94 · cited 1×
“Depression also significantly worsenedpatient-centeredoutcomesandwasassociatedwith dialysis initiation, lower quality of life, greater symptomburden,sexualdysfunction,andnonadherencetomedicationsand dietary restrictions.(10,11) Evidence for placebo-controlled efficacy of commonly used antidepressants, such as selectiv…”
Taraz, M., Khatami, M., Dashti‐Khavidaki, S., Akhondzadeh, S., Noorbala, A.-A., Ghaeli, P., & Taraz, S. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.09.020 · Cited by 86 · cited 1×
“The mean (SD) sertraline doses were 65 (29) mg/d and 68.”
Angermann, C. E., Gelbrich, G., Störk, S., Fallgatter, A. J., Deckert, J., Faller, H., & Ertl, G. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.10.005 · Cited by 83 · cited 1×
“Few data exist regarding SSRI safety among patients with CKD because such patients have been excluded from large antidepressant medication trials.(12,13,39) Patients with advanced CKD are at a higher risk for antidepressant adverse events due to the potential accumulation of toxic metabolite effects in the setting of…”
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H., O’Connor, C. M., & Califf, R. M. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00908-x · Cited by 73 · cited 4×
“Few data exist regarding SSRI safety among patients with CKD because such patients have been excluded from large antidepressant medication trials.(12,13,39) Patients with advanced CKD are at a higher risk for antidepressant adverse events due to the potential accumulation of toxic metabolite effects in the setting of…”
InfluentialPREDICTIVE SOCIOECONOMIC AND CLINICAL PROFILES OF ANTIDEPRESSANT RESPONSE AND REMISSION
Jain, F. A., Hunter, A. M., Brooks, J. O., & Leuchter, A. F. (2013) · Depression and Anxiety · doi:10.1002/da.22045 · Cited by 63 · cited 1×
“Another potential reason for lack of efficacy is that 84% of participants were unemployed, and socioeconomic factors such as unemployment were shown to be associated with a low likelihood of antidepressant treatment response.(38) Inaddition to investigating theefficacyofacommonlyprescribedSSRI amongpatientswithCKD, th…”
Major depression in renal dialysis patients: an open trial of antidepressant therapy.
Kennedy, S. H., Jl, C., Rodin, G., & Roin, G. M. (1989) · PubMed · Cited by 60
Wuerth, D. B., Finkelstein, S. H., Kliger, A. S., & Finkelstein, F. O. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16094.x · Cited by 53
Atalay, H., Solak, Y., Bıyık, M., Bıyık, Z., Yeksan, M., Uğuz, F., Güney, İ., Tonbul, H. Z., & Türk, S. (2009) · International Urology and Nephrology · doi:10.1007/s11255-009-9686-y · Cited by 49
Treatment with antidepressive drugs improved quality of life in chronic hemodialysis patients
Türk, Ş. B., Atalay, H., Altıntepe, L., Güney, İ., Okudan, N., Tonbul, H. Z., Gökbel, H., Kucur, R., Yeksan, M., & Yıldız, A. (2006) · Clinical Nephrology · doi:10.5414/cnp65113 · Cited by 48
Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST)
Jain, N., Trivedi, M. H., Rush, A. J., Carmody, T. J., Kurian, B. T., Toto, R. D., Sarode, R., & Hedayati, S. S. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.10.004 · Cited by 32 · cited 5×
“Detailed methods were published.(15) The trial protocol appears in Supplement 1.”
InfluentialSelf-citationSensitivity Analysis for Pattern Mixture Models
Curran, D., Molenberghs, G., Thijs, H., & Verbeke, G. N. (2004) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-120028510 · Cited by 20 · cited 1×
“Given that (1) the amount of missing primary outcome data was small, (2) mixedeffects models allow inclusion of participants with missing data, and (3) these models are unbiased when data are missing at random, imputation of missing data was not done.(26) The proportion experiencing an adverse event; themaximum SAFTEE…”
Jain, N., Carmody, T. J., Minhajuddin, A., Toups, M. S. P., Trivedi, M. H., Rush, A. J., & Hedayati, S. S. (2016) · American Journal of Nephrology · doi:10.1159/000448598 · Cited by 14 · cited 11×
“This instrument was previously validated for depression screening and shown to be independently associatedwith outcomes among individuals with CKD.(16,17) Individuals who provided consent completed the Mini International Neuropsychiatric Interview,(18) which is based on the Diagnostic and Statistical Manual of Mental…”
InfluentialSelf-citationWork and Social Adjustment Scale
Marks, I. M. (1986) · PsycTESTS Dataset · doi:10.1037/t77117-000 · Cited by 8
Initial Severity and Antidepressant Benefits
Maksimowski, M., & Qayyum, Z. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190625085.003.0026 · Cited by 2 · cited 1×
“Amean antidepressant drug-placebo difference of 3 points or greater on the Hamilton Rating Scale of Depression is recommended as a criterion for clinical significancewhenestablishingguidelines for the treatment of depression.(25) This is equivalent to a difference of 2 points on the QIDS-C16, which was regarded as the…”
Cited by
Sorted by citations
Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S. P., Lentine, K. L., Lerma, E. V., Mezue, K. N., Molitch, M. E., Müllens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,535
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Gregg, L. P., Bossola, M., Ostrosky-Frid, M., & Hedayati, S. S. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.19891220 · Cited by 187
“In the CKD Antidepressant Sertraline Trial, a randomized, double-blinded trial of antidepressant therapy in 201 patients with nondialysis CKD, treatment with sertraline versus placebo did not result in improvement in fatigue, measured by the SF-36 vitality score (95).”
Self-citationMehrotra, R., Cukor, D., Unruh, M. L., Rue, T. C., Heagerty, P. J., Cohen, S. D., Dember, L. M., Díaz‐Linhart, Y., Dubovsky, A. N., Greene, T., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2229 · Cited by 118
Self-citationDepression, Anxiety, and Cognitive Impairment
Angermann, C. E., & Ertl, G. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0414-8 · Cited by 108
Metadata
- Authors
- Hedayati, S. S., Gregg, L. P., Carmody, T., Jain, N., Toups, M., Rush, A. J., Toto, R. D., & Trivedi, M. H.
- Affiliations
- VA North Texas Health Care System (US)
- The University of Texas Southwestern Medical Center (US)
- Central Arkansas Veterans Healthcare System (US)
- The University of Texas at Austin (US)
- Duke University (US)
- Corresponding author
- Hedayati, S. Susan
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-11-21
- Volume
- 318
- Issue
- 19
- Pages
- 1876
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5710375
- OpenAlex
- W2766107670
- Cited by
- 129
- References
- 45
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 16 · 2023: 10 · 2022: 12 · 2021: 14 · 2020: 15 · 2019: 19 · 2018: 22 · 2017: 1
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 CX000217)
- National Institutes of Health (UL1TR001105)
- National Institute of Mental Health (K23MH104768)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK085512, P30DK079328)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- sertraline, chronic kidney disease, major depressive disorder, depressive symptoms, selective serotonin reuptake inhibitors, antidepressant efficacy, quality of life, adverse events, predialysis, CAST trial, adverse drug reactions, drug safety in renal impairment
- MeSH terms
- Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Quality of Life, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Sertraline, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
